A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With de Novo Native Coronary Artery Lesions
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms ABSORB; ABSORB-B
- Sponsors Abbott Vascular
- 03 Mar 2016 Results published in the Circulation Journal (n = 90).
- 24 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 23 Feb 2016 Results of five-year follow up study published in the Journal of the American College of Cardiology